Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2466752 | 0.93 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL13640250 | 0.92 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL2529262 | 0.90 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL3624680 | 0.90 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL12926419 | 0.89 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL2463045 | 0.89 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL2468216 | 0.88 | PIK3CD (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL12013097 | 0.85 | PIK3CD (0.78) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL3619688 | 0.85 | PIK3CD (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL13640264 | 0.85 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.